5-alpha reductase inhibitors finasteride and dutasteride are associated with reductions in sperm count, sperm concentration, and motility, hormonal alterations, and variable sexual dysfunction that may persist after discontinuation, with mechanistic studies revealing impacts on spermatogenesis gene expression and penile tissue signaling.
Key Findings
Results
Finasteride and dutasteride were associated with reductions in sperm count of 34% and 29%, respectively, along with decreases in sperm concentration and motility.
Finasteride was associated with a 34% reduction in sperm count across reviewed studies.
Dutasteride was associated with a 29% reduction in sperm count across reviewed studies.
Both drugs were also associated with reductions in sperm concentration and motility.
These findings were synthesized from randomized controlled trials, observational studies, and mechanistic investigations.
Results
Hormonal alterations associated with 5-alpha reductase inhibitor use included increased testosterone levels and variable changes in dihydrotestosterone, estradiol, progesterone, and androstenedione levels.
Both finasteride and dutasteride were associated with increased testosterone levels.
Changes in dihydrotestosterone levels were observed, consistent with the mechanism of 5-alpha reductase inhibition.
Variable changes were noted in estradiol, progesterone, and androstenedione levels.
These hormonal alterations were identified across the reviewed clinical and experimental literature.
Results
Sexual dysfunction findings were variable, with some studies demonstrating persistent decreased libido, erectile dysfunction, and reduced penile sensitivity months to years after discontinuation of the drugs.
Sexual dysfunction effects included decreased libido, erectile dysfunction, and reduced penile sensitivity.
Notably, these effects persisted in some patients months to years after discontinuation of the medication.
Findings related to sexual dysfunction were described as 'variable' across the reviewed studies.
Persistence of symptoms after drug discontinuation suggests potential long-term or irreversible effects in a subset of patients.
Results
Mechanistic studies in rodents revealed significant reductions in the expression of genes critical to spermatogenesis, including Dazl, Prm2, Sycp3, and Tsga10.
Genes identified as affected include Dazl, Prm2, Sycp3, and Tsga10, all described as critical to spermatogenesis.
These findings were derived from experimental studies conducted in rodent models.
Gene expression reductions were described as 'significant.'
These molecular findings provide potential mechanistic explanations for the observed clinical reductions in sperm parameters.
Results
Mechanistic studies in rodents revealed alterations in penile tissue contractility and nitric oxide synthase signaling associated with 5-alpha reductase inhibitor exposure.
Alterations were observed in both penile tissue contractility and nitric oxide synthase signaling pathways.
These findings were identified in rodent experimental models.
These mechanistic changes provide potential biological explanations for the observed sexual dysfunction, including erectile dysfunction.
Nitric oxide synthase signaling is a recognized pathway involved in erectile function.
Discussion
The growing use of combination therapies targeting multiple 5-alpha reductase isotypes raises the potential for additive or synergistic reproductive effects beyond those seen with single-drug regimens.
Current evidence focuses primarily on single drug regimens of finasteride or dutasteride.
Combination therapies targeting multiple 5-alpha reductase isotypes are described as increasingly used.
The authors note the potential for 'additive or synergistic reproductive effects' with combination approaches.
The review identifies this as a gap in current literature requiring further investigation.
Conclusions
The adverse reproductive effects of 5-alpha reductase inhibitors appear to affect only a subset of patients, and long-term data remain limited.
The review characterizes reproductive effects as occurring in 'a subset of patients' rather than universally.
Variability in outcomes was noted across reviewed studies.
Long-term reproductive data are described as limited.
The authors call for further research particularly in younger populations and with combination therapies.
The review covers outcomes including sperm parameters, hormonal profiles, sexual function, and potential long-term reproductive effects.
Background
Androgenic alopecia affects a significant portion of the population and has impacts on self-esteem and quality of life, making 5-alpha reductase inhibitors widely used treatments.
Androgenic alopecia is commonly known as male pattern baldness (MPB).
5-alpha reductase inhibitors increase hair density by reducing dihydrotestosterone levels.
Both finasteride and dutasteride are widely used for this indication.
The widespread use in men of reproductive age is identified as a reason why reproductive effects are a particular concern.
What This Means
This research reviews what is currently known about how two common hair loss medications — finasteride and dutasteride — affect male reproductive health. Both drugs work by blocking an enzyme that converts testosterone into a more potent hormone called dihydrotestosterone (DHT), which slows or reverses male pattern baldness. However, this same hormonal pathway plays important roles in sperm production and sexual function. By analyzing data from clinical trials, observational studies, and laboratory experiments, the reviewers found that both medications were associated with meaningful reductions in sperm count (about 34% for finasteride and 29% for dutasteride), as well as decreases in sperm concentration and sperm movement. Hormonal levels also shifted, including increases in testosterone and changes in other sex hormones.
One of the more concerning findings is that sexual side effects — including reduced sex drive, erectile dysfunction, and decreased penile sensitivity — were reported to persist in some men for months or even years after stopping the medication. Laboratory studies in rodents helped explain some of these effects by showing that these drugs reduce the activity of genes essential for sperm production and alter the biology of penile tissue in ways that could impair sexual function. These mechanistic findings suggest real biological changes, not just statistical associations.
This research suggests that while finasteride and dutasteride are effective treatments for hair loss, they carry potential reproductive risks that may be especially relevant for younger men who may wish to have children. The review also flags a growing concern about combination therapies that target multiple forms of the enzyme, which could have even greater reproductive impacts than either drug alone. The authors conclude that more long-term research is needed, particularly in younger patients and those using combination treatments, to fully understand and characterize these risks.
Check Your Own Numbers
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.
T. Quintero, B. Gratz, Luke Pepperney, Jake Rosenstadt, G. I. Gallicano. (2026). Impact of 5-alpha reductase inhibitors on male reproductive health: A review of finasteride and dutasteride.. Reproductive Toxicology. https://doi.org/10.1016/j.reprotox.2026.109257